ValuEngine upgraded shares of CELYAD SA/ADR (NASDAQ:CYAD) from a hold rating to a buy rating in a research note released on Thursday, ValuEngine reports.
Several other analysts have also recently weighed in on CYAD. Zacks Investment Research cut CELYAD SA/ADR from a buy rating to a hold rating in a report on Wednesday, July 17th. Piper Jaffray Companies dropped their price objective on CELYAD SA/ADR from $41.00 to $25.00 and set an overweight rating for the company in a report on Friday, July 5th. HC Wainwright reissued a buy rating and set a $48.00 price objective (down from $52.00) on shares of CELYAD SA/ADR in a report on Friday, July 5th. Finally, William Blair reissued a buy rating on shares of CELYAD SA/ADR in a report on Monday, May 13th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus price target of $31.33.
NASDAQ CYAD traded down $0.51 on Thursday, hitting $11.50. 46,710 shares of the company were exchanged, compared to its average volume of 12,790. The company has a market cap of $112.15 million, a P/E ratio of -2.90 and a beta of 1.25. CELYAD SA/ADR has a 1-year low of $10.59 and a 1-year high of $32.18. The company has a current ratio of 5.36, a quick ratio of 5.36 and a debt-to-equity ratio of 0.02. The firm’s 50 day simple moving average is $13.47.
A hedge fund recently raised its stake in CELYAD SA/ADR stock. Victory Capital Management Inc. boosted its position in shares of CELYAD SA/ADR (NASDAQ:CYAD) by 4.0% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 672,331 shares of the company’s stock after purchasing an additional 25,980 shares during the quarter. Victory Capital Management Inc. owned about 6.81% of CELYAD SA/ADR worth $13,716,000 as of its most recent filing with the Securities and Exchange Commission. 7.28% of the stock is currently owned by institutional investors and hedge funds.
About CELYAD SA/ADR
Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead drug product candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma.
Recommended Story: Stock Symbols, CUSIP and Other Stock Identifiers
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for CELYAD SA/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELYAD SA/ADR and related companies with MarketBeat.com's FREE daily email newsletter.